Clinical Trials Browser

Interventional × Denosumab × Clear all

NCT02833610 2026-02-18

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Phase 2 Completed

Multiple Myeloma

NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

Phase 2 Completed

20 enrolled 8 charts

Smoldering Multiple Myeloma

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04549207 2025-11-28

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Phase 4 Active not recruiting

Breast Neoplasms

NCT04067726 2025-10-16

TRIDENT

Phase 2 Active not recruiting

Breast Neoplasms

NCT04586660 2025-10-01

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Phase 4 Active not recruiting

Giant Cell Tumor of Bone

NCT06513624 2025-07-25

ETC-159-02

Phase 1 Recruiting

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

NCT07043608 2025-07-02

ZAMBONI

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT04907539 2025-04-16

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Phase 2 Completed

25 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT04711109 2025-04-02

BRCA-P

Phase 3 Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasms

NCT03792763 2025-02-11

DEFENCE

Phase 2 Completed

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06749886 2024-12-27

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Phase 2 Recruiting

Lung Neoplasms

NCT03629717 2024-10-16

RANKL Inhibition and Breast Tissue Biomarkers

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT03869762 2024-09-25

DICE

Phase 2 Terminated

Neoplasm Metastasis, Prostatic Neoplasms

NCT03620019 2024-08-12

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Phase 2 Completed

25 enrolled 16 charts

Melanoma

NCT03301857 2024-05-20

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Phase 4 Completed

85 enrolled 13 charts

Giant Cell Tumor of Bone

NCT03401060 2024-05-03

DenosuMast

Phase 3 Completed

Osteoporosis, Mastocytosis, Systemic

NCT02470091 2024-01-22

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase 2 Completed

56 enrolled 18 charts

Osteosarcoma

NCT03324932 2023-10-06

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT00556374 2023-07-27

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Phase 3 Completed

3,420 enrolled 19 charts

Breast Neoplasms

NCT05813665 2023-04-19

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Phase 3 Not yet recruiting

Giant Cell Tumor of Bone

NCT03280667 2023-03-29

KEYPAD

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00321464 2022-11-08

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Phase 3 Completed

2,049 enrolled 16 charts

Breast Neoplasms, Fractures, Bone

NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Phase 3 Completed

1,718 enrolled 22 charts

Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00330759 2022-11-07

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Phase 3 Completed

1,779 enrolled 14 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Spinal Cord Compression

NCT03382574 2022-06-14

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Phase EARLY_PHASE1 Terminated

Ovarian Neoplasms

NCT03161756 2022-04-07

CHARLI

Phase 1/2 Unknown

Melanoma

NCT03732495 2022-03-29

LENVOS

Phase 2 Unknown

EndocrineHead & Neck

Thyroid Cancer Metastatic

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT01951586 2021-10-25

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

226 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03408652 2021-10-22

MOSCAR

Phase 3 Terminated

Carcinoma, Renal Cell

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Phase 2 Completed

45 enrolled 7 charts

Breast Neoplasms

NCT01077154 2021-09-28

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Phase 3 Terminated

4,509 enrolled 25 charts

Breast Neoplasms

NCT04859569 2021-06-07

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Phase 3 Unknown

Other solid neoplasm

Bone Metastases From Solid Tumors

NCT03027557 2021-05-25

DENOCINA

Phase 3 Completed

46 enrolled 49 charts

Parathyroid Neoplasms, Hyperparathyroidism, Primary

NCT04798326 2021-03-15

MW032

Phase 1 Completed

Bone Neoplasms

NCT01624766 2021-02-25

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02682693 2021-02-02

GeparX

Phase 2 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT03620149 2021-01-06

REDUCE

Phase 2 Terminated

Giant Cell Tumor of Bone

NCT04550949 2020-09-22

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Phase 3 Unknown

Bone Metastases

NCT04494373 2020-08-04

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Phase 1 Unknown

Other solid neoplasm

Bone Metastasis From Solid Tumors

NCT03532087 2020-01-18

PERIDENO

Phase 2 Withdrawn

Breast Neoplasms

NCT01545648 2020-01-02

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Phase 2 Terminated

4 enrolled 7 charts

Neoplasms

NCT01952054 2019-11-22

Denosumab for Breast Cancer With Bone Mets

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Phase 2 Terminated

1 enrolled 7 charts

Prostatic Neoplasms

NCT01419717 2019-09-24

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Phase 3 Completed

129 enrolled 10 charts

BreastGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms

NCT03605199 2019-08-26

Denosumab in Subjects With Giant Cell Rich Tumors of Bone

Phase 2 Unknown

Chondroblastoma, Granuloma, Giant Cell, Bone Cysts, Aneurysmal, Osteoblastoma

NCT03811509 2019-01-28

B-ABLE

Phase 4 Unknown

Breast Neoplasms, Osteoporosis, Arthralgia, Osteoporotic Fractures, Musculoskeletal Pain

NCT01864798 2018-11-27

D-Beyond

Phase 2 Terminated

Breast Neoplasms

NCT03070002 2018-11-20

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Phase 2 Terminated

1 enrolled 6 charts

Breast Neoplasms, Neoplastic Cells, Circulating